For the latest media releases and news about Pharmaxis Ltd, please select from the following articles. Material news announcements made by Pharmaxis are first filed with the Australian Securities Exchange (ASX) and are also available on the ASX website.
Syntara doses first patient in Phase 2 trial of patients with sleep disorder at risk of Parkinson’s disease
Clinical stage drug developer Syntara1 today announced that the first patient has been dosed in its randomised double-blind placebo controlled Phase 2 study of the Syntara drug discovery PXS-4728 studying patients with isolated Rapid Eye Movement Sleep Behaviour Disorder (iRBD) who are at risk of Parkinson’s disease.
The first patient has been dosed in Sydney in a multi-national trial that is majority funded by the Parkinson’s Virtual Biotech, the international drug discovery and development program founded by Parkinson’s UK.
1. At the 2023 annual general meeting to be held on 28 November 2023, Pharmaxis shareholders will be asked to approve a change in the name of the company from Pharmaxis Ltd to Syntara Limited (ASX: SNT).Read full media release - pdf
Pharmaxis Ltd (ASX: PXS) will release its Quarterly Shareholder Update on the morning of 31 October 2023.
Investors and analysts are invited to participate in a virtual investor briefing by the Company’s chief executive officer Mr Gary Phillips at 10.00am AEDT on Tuesday 31 October 2023.
The event will consist of a short presentation of the Company’s progress over the past quarter and future plans followed by a Q&A session from attendees.
The event is free to attend, and investors should register in advance using the following registration link:
Upon registration, instructions for joining the session will be sent via email.
To ensure as many questions as possible can be responded to in the allotted time, Pharmaxis welcomes investors to pre-submit questions by emailing them to: email@example.comRead full media release - pdf
The 2023 Annual General Meeting of Pharmaxis will be held as a virtual meeting on Tuesday, 28 November 2023 at 11:00 am (Sydney time).
The notice of meeting, explanatory statement and proxy form was made available to shareholders on 26 October 2023. The notice of meeting together with a sample proxy form is available here.
The 2023 statutory annual report is available here.